Tom R Denee (Tom Denee)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 5

Top Venues

Advances in therapy

Journal of medical economics

Janssen-Cilag Ltd

Universiteit Utrecht Faculteit Bètawetenschappen (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Janssen-Cilag Ltd Feb 15 2018

United Kingdom

Senior Manager :: Health Economics Market Access Reimbursement

Janssen Pharmaceutica NV Oct 01 2014 - Feb 14 2018

Netherlands

Manager Market Access :: Health Economics, Market Access and Reimbursement

Crucell NV Nov 01 2010 - Sep 30 2014

Netherlands

Business Manager :: Business Management

Education History

Universiteit Utrecht Faculteit Bètawetenschappen Sep 01 2001 - Jul 01 2008

Netherlands

MSC :: Pharmaceutical Sciences

Publications

Katalin Pungor, Jennifer Lee, Tom R Denee, Yerkebulan Kambarov, Riikka Nissinen, Kevin Ampeh, Marco Pellegrini, Francesco Parmeggiani
Impacts of X-linked Retinitis Pigmentosa and Patient Pathways in European Countries: Results from the Cross-sectional EXPLORE XLRP-1 Physician Survey. Advances in therapy 41 (8) (2024)
Katalin Pungor, Jennifer Lee, Tom R Denee, Yerkebulan Kambarov, Riikka Nissinen, Kevin Ampeh, Marco Pellegrini, Francesco Parmeggiani
Impacts of X-linked Retinitis Pigmentosa and Patient Pathways in European Countries: Results from the Cross-sectional EXPLORE XLRP-1 Physician Survey. Advances in therapy 41 (8) (2024)
Katalin Pungor, Jennifer Lee, Tom R Denee, Yerkebulan Kambarov, Riikka Nissinen, Kevin Ampeh, Marco Pellegrini, Francesco Parmeggiani
Impacts of X-linked Retinitis Pigmentosa and Patient Pathways in European Countries: Results from the Cross-sectional EXPLORE XLRP-1 Physician Survey. Advances in therapy (2024)
Katalin Pungor, Jennifer Lee, Tom R Denee, Yerkebulan Kambarov, Riikka Nissinen, Kevin Ampeh, Marco Pellegrini, Francesco Parmeggiani
Impacts of X-linked Retinitis Pigmentosa and Patient Pathways in European Countries: Results from the Cross-sectional EXPLORE XLRP-1 Physician Survey. Advances in therapy 41 (8) (2024)
Thomas R Einarson, Basil G Bereza, Fadi Tedouri, Kristel Van Impe, Tom R Denee, Pieter J T Dries
Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands. Journal of medical economics 20 (11) (2017)

Tom R Denee.css-eqlu8i{font-size:small;padding-left:4px;} (Tom Denee)

Publication Activity (10 Years)

Top Topics

Top Venues

Tom R Denee (Tom Denee)